Clinical Trial

A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is an open-label, multicenter Phase IB/II clinical trial to evaluate the safety, tolerability and efficacy of SHR-9839 for injection in combination with other antitumor therapies in patients with advanced solid tumors.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-06 -> 2029-06 2026-05-12
minor Completion pushed: 2027-06 -> 2029-12 2026-05-12
Trial Details
NCT Number NCT06474455
Lead Sponsor Shanghai Hengrui Pharmaceutical Co., Ltd.
Conditions Advanced Solid Tumors
Enrollment 156 participants
Start Date 2024-07-02
Primary Completion 2029-06 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-11